Data-driven prediction of drug effects and interactions

Science Translational Medicine

Volumn 4, Issue 125, 2012, Pages

  Tatonetti, Nicholas P ^a,b   Ye, Patrick P ^b   Daneshjou, Roxana ^a   Altman, Russ B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADVERSE OUTCOME; ANALYTICAL ERROR; ARTICLE; CONTROLLED STUDY; DATA SYNTHESIS; DRUG ANTAGONISM; DRUG CLASSIFICATION; DRUG EFFECT; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; ELECTRONIC MEDICAL RECORD; HUMAN; OFF LABEL DRUG USE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REFERENCE DATABASE; TREATMENT INDICATION; DRUG INTERACTION; DRUG TOXICITY; METHODOLOGY; POSTMARKETING SURVEILLANCE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG INTERACTIONS; DRUG TOXICITY; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84858329412     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003377     Document Type: Article

References (34)

1. D. W. Bates, D. J. Cullen, N. Laird, L. A. Petersen, S. D. Small, D. Servi, G. Laffel, B. J. Sweitzer, B. F. Shea, R. Hallisey, M. V. Vliet, R. Nemeskal, L. L. Leape, ADE Prevention Study Group; L. L. Leape, D. Servi, N. Laird, D. Bates, P. Hojnowski-Diaz, L. A. Petersen, S. Petrycki, M. V. Vliet, M. Cotugno, H. Patterson, B. F. Shea, M. Hickey, S. Kleefield, J. Cooper, D. J. Cullen, E. Kinneally, R. Nemeskal, B. J. Sweitzer, S. D. Small, H. J. Demonaco, M. D. Clapp, R. Hallisey, T. Gallivan, J. Ives, K. Porter, B. T. Thompson, G. Laffel, J. R. Hackman, A. Edmondson, Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 274, 29-34 (1995).
2. D. C. Classen, S. L. Pestotnik, R. S. Evans, J. F. Lloyd, J. P. Burke, Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301-306 (1997).
3. A. Szarfman, J. M. Tonning, P. M. Doraiswamy, Pharmacovigilance in the 21st century: New systematic tools for an old problem. Pharmacotherapy 24, 1099-1104 (2004).
4. A. Bate, S. J. Evans, Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf. 18, 427-436 (2009).
5. A. Szarfman, S. G. Machado, R. T. O'Neill, Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25, 381-392 (2002).
6. W. DuMouchel, Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53, 177-190 (1999).
7. G. N. Norén, A. Bate, R. Orre, I. R. Edwards, Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat. Med. 25, 3740-3757 (2006).
8. J. Hopstadius, G. N. Norén, A. Bate, I. R. Edwards, Impact of stratification on adverse drug reaction surveillance. Drug Saf. 31, 1035-1048 (2008).
9. E. F. Cook, L. Goldman, Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score. J. Clin. Epidemiol. 42, 317-324 (1989).
10. M. S. Cepeda, R. Boston, J. T. Farrar, B. L. Strom, Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am. J. Epidemiol. 158, 280-287 (2003).
11. O. Kuss, T. Legler, J. Börgermann, Treatments effects from randomized trials and propensity score analyses were similar in similar populations in an example from cardiac surgery. J. Clin. Epidemiol. 64, 1076-1084 (2011).
12. M. Kuhn, M. Campillos, I. Letunic, L. J. Jensen, P. Bork, A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010).
13. M. Campillos, M. Kuhn, A.-C. Gavin, L. J. Jensen, P. Bork, Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
14. L. Yang, P. Agarwal, Systematic drug repositioning based on clinical side-effects. PLoS One 6, e28025 (2011).
15. J. Hopstadius, G. N. Norén, A. Bate, I. R. Edwards, Stratification for spontaneous report databases. Drug Saf. 31, 1145-1147 (2008).
16. J. Scheiber, J. L. Jenkins, S. C. Sukuru, A. Bender,D. Mikhailov, M.Milik, K. Azzaoui, S. Whitebread, J. Hamon, L. Urban, M. Glick, J. W. Davies, Mapping adverse drug reactions in chemical space. J. Med. Chem. 52, 3103-3107 (2009).
17. J. Scheiber, B. Chen, M. Milik, S. C. Sukuru, A. Bender, D. Mikhailov, S. Whitebread, J. Hamon, K. Azzaoui, L. Urban, M. Glick, J. W. Davies, J. L. Jenkins, Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J. Chem. Inf. Model. 49, 308-317 (2009).
18. L. Xie, J. Li, L. Xie, P. E. Bourne, Drug discovery using chemical systems biology: Identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput. Biol. 5, e1000387 (2009).
19. A. Cami, A. Arnold, S. Manzi, B. Reis, Predicting adverse drug events using pharmacological network models. Sci. Transl. Med. 3, 114ra127 (2011).
20. S. N. Deftereos, C. Andronis, E. J. Friedla, A. Persidis, A. Persidis, Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 323-334 (2011).
21. C. V. Fletcher, Drug interactions should be evaluated in patients. Clin. Pharmacol. Ther. 88, 585-587 (2010).
22. M. Pirmohamed, Drug-drug interactions and adverse drug reactions: Separating the wheat from the chaff. Wien. Klin. Wochenschr. 122, 62-64 (2010).
23. F. Montastruc, A. Sommet, E. Bondon-Guitton, G. Durrieu, E. Bui, H. Bagheri, M. Lapeyre-Mestre, L. Schmitt, J. L. Montastruc, The importance of drug-drug interactions as a cause of adverse drug reactions: A pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur. J. Clin. Pharmacol., 10.1007/s00228-011-1156-7 (2011).
24. R. Leone, L. Magro, U. Moretti, P. Cutroneo, M. Moschini, D. Motola, M. Tuccori, A. Conforti, Identifying adverse drug reactions associated with drug-drug interactions: Data mining of a spontaneous reporting database in Italy. Drug Saf. 33, 667-675 (2010).
25. G. N. Norén, R. Sundberg, A. Bate, I. R. Edwards, A statistical methodology for drug-drug interaction surveillance. Stat. Med. 27, 3057-3070 (2008).
26. R. Harpaz, H. S. Chase, C. Friedman, Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics 11 (Suppl. 9), S7 (2010).
27. L. Tari, S. Anwar, S. Liang, J. Cai, C. Baral, Discovering drug-drug interactions: A text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics 26, i547-i553 (2010).
28. B. Percha, Y. Garten, R. B. Altman, Discovery and explanation of drug-drug interactions via text mining. Pac. Symp. Biocomput. 410-421 (2012).
29. M. Takarabe, D. Shigemizu, M. Kotera, S. Goto, M. Kanehisa, Network-based analysis and characterization of adverse drug-drug interactions. J. Chem. Inf. Model. 51, 2977-2985 (2011).
30. S.-F. Lin, K.-T. Xiao, Y.-T. Huang, C.-C. Chiu, V.-W. Soo, Analysis of adverse drug reactions using drug and drug target interactions and graph-based methods. Artif. Intell. Med. 48, 161-166 (2010).
31. S. I. Berger, R. Iyengar, Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472 (2009).
32. M. P. Fichman, H. Vorherr, C. R. Kleeman, N. Telfer, Diuretic-induced hyponatremia. Ann. Intern. Med. 75, 853-863 (1971).
33. E. Friedman, M. Shadel, H. Halkin, Z. Farfel, Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann. Intern. Med. 110, 24-30 (1989).
34. W. L. ten Holt, C. E. van Iperen, G. Schrijver, A. K. Bartelink, Severe hyponatremia during therapy with fluoxetine. Arch. Intern. Med. 156, 681-682 (1996).